Caliway Biopharmaceuticals C, TW0006919004

Caliway reported phase 2 results: what it means for Caliway Biopharmaceuticals C stock

Published on 10/12/2026 at 10:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CBL-0202DD achieved its primary endpoint on September 21, 2026. For Caliway Biopharmaceuticals C stock, this means 3 phase 3 studies.

Key points in brief

Caliway reported positive phase 2 results for CBL-0202DD on September 21, 2026.
SUPREME-01 is expected to enroll 320 participants in the United States and Canada.
EASD data showed 69.60 percent of treated participants reduced subcutaneous fat by at least 150 mL.
Caliway's pipeline includes 3 phase 3 studies, with first results expected at the end of 2027.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway reported positive phase 2 results for CBL-0202DD on September 21, 2026, with the study achieving its primary efficacy endpoint for Dercum's disease. MarketScreener reported that CBL-514 delivered statistically significant pain reduction in the full analysis set and per-protocol population. The result gives Caliway Biopharmaceuticals C stock a clinical milestone beyond the company's aesthetic medicine program.

Three milestones shape the pipeline

On September 21, 2026, Caliway announced the phase 2 Dercum's disease result for CBL-0202DD. On September 23, 2026, the company dosed the first participant in SUPREME-01, a global phase 3 trial evaluating CBL-514 for large-area abdominal fat reduction. Caliway said the study is expected to enroll 320 participants across the United States and Canada.

On October 2, 2026, Caliway published new EASD data on subcutaneous and visceral fat. Caliway said 69.60 percent of treated participants achieved at least 150 mL of subcutaneous fat reduction at the eight-week follow-up, compared with 0.00 percent for placebo. The comparison is the clearest quantified signal in the current development story, although it remains a phase 2 result rather than a regulatory approval.

What phase 3 adds

SUPREME-01 shifts the evidence base from early efficacy to a larger, placebo-controlled test. The study requires a two-grade improvement on both the Patient-Reported Abdominal Fat Rating Scale and the Clinician-Reported Abdominal Fat Rating Scale, with MRI-based assessments as a key secondary endpoint.

TrialT ticker lists SUPREME-01 as a phase 3 study with 320 planned participants and an estimated completion in September 2027. The same source identifies 3 phase 3 studies in Caliway's pipeline, compared with 1 in the prior 12-month period. Caliway's own release says first results from the abdominal fat program are expected at the end of 2027.

Clinical evidence remains the key test

The EASD report provides a quantified comparison, but its data came from a phase 2 subgroup. HCPLive described a 46-patient analysis in which visceral fat fell by 10.90 percent with CBL-514 and rose by 4.60 percent with placebo at week four, a treatment difference of 15.50 percentage points. For Caliway Biopharmaceuticals C stock, the next decisive evidence will come from the larger phase 3 program and its predefined endpoints.